STEGLUJAN

PeakSM

ertugliflozin and sitagliptin

NDAORALTABLET
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1

Clinical Trials (1)

NCT02099110Phase 3Completed

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Started Apr 2014
1,233 enrolled
Type 2 Diabetes Mellitus

Loss of Exclusivity

LOE Date
Oct 21, 2030
56 months away
Patent Expiry
Oct 21, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
7326708
Nov 24, 2026
SubstanceProduct
U-2214
7326708*PED
May 24, 2027
8080580
Jul 13, 2030
SubstanceProduct
U-2214
9308204
Oct 21, 2030
Product
9439901
Oct 21, 2030
U-2214